Keyphrases
Neonate
100%
Prolonged Use
100%
Paracetamol
100%
Ethanol
30%
Pain Score
30%
Bilirubin
20%
Ethics
20%
Alanine Aminotransferase
20%
Inclusion Process
10%
Population Pharmacokinetic Analysis
10%
Treatment Discontinuation
10%
Pain Relief
10%
Steady State
10%
Metabolism
10%
Clinical Trials
10%
Concomitant Treatment
10%
Prolonged Pain
10%
Plasma Concentration
10%
One-compartment Model
10%
Postmenstrual Age
10%
EudraCT
10%
First-order
10%
Blood Samples
10%
Neonatal Intensive Care Unit
10%
Gestational Age
10%
Treatment Initiation
10%
Phenobarbital
10%
Dosing Strategy
10%
Potential Risk
10%
Nonlinear Mixed Effects
10%
Two-compartment Model
10%
Pain in Neonate
10%
Agricultural and Biological Sciences
Neonate
100%
Bilirubin
40%
Transaminase
40%
Alanine
40%
Ethics
40%
Metabolite
40%
Blood Plasma
40%
Pharmacokinetic
20%
Gestational Age
20%
Excipient
20%
Pharmacology, Toxicology and Pharmaceutical Science
Paracetamol
100%
Cohort Study
100%
Alanine Aminotransferase
18%
Bilirubin
18%
Biological Marker
18%
Phenobarbital
9%
Pharmacokinetic
9%
Clinical Trial
9%
Elimination
9%
Excipient
9%